Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer

International Journal of Oncology

Volumn 51, Issue 6, 2017, Pages 1793-1800

  Rousseau, Aurélie ^a,b   Van Dreden, Patrick ^b   Khaterchi, Amir ^c   Larsen, Annette K ^a   Elalamy, Ismail ^a,c   Gerotziafas, Grigoris T ^a,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b Clinical Research Department   (France)

^c HÔPITAL TENON   (France)

Author keywords

Cancer; Hypercoagulability; Microparticles; Thrombin Generation; Tissue Factor

Indexed keywords

CANCER CELL DERIVED MICROPARTICLE; NANOPARTICLE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; BXPC-3 CELL LINE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MCF-7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING; BREAST TUMOR; FEMALE; MEMBRANE MICROPARTICLE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; PLASMA; THROMBOCYTE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOCARCINOMA; BLOOD COAGULATION; BLOOD PLATELETS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL-DERIVED MICROPARTICLES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; PANCREATIC NEOPLASMS; PLASMA; THROMBIN;

EID: 85033493404     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2017.4170     Document Type: Article

References (38)

1. Khorana AA, Francis CW, Culakova E, Kuderer NM and Lyman GH: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5: 632-634, 2007.
2. Falanga A and Russo L: Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 32: 115-125, 2012.
3. Trousseau A: Phlegmasia Alba Dolens. In: Clinique Medicale de l'Hotel-dieu de Paris. Vol. 3. JB Balliere et Fils, Paris, pp654-712, 1865.
4. Sørensen HT, Mellemkjaer L, Olsen JH and Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343: 1846-1850, 2000.
5. Riewald M and Ruf W: Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 98: 7742-7747, 2001.
6. Aharon A and Brenner B: Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 22: 61-69, 2009.
7. Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P and López JA: Microvesicle-Associated tissue factor and Trousseau's syndrome. J Thromb Haemost 5: 70-74, 2007.
8. Tilley RE, Holscher T, Belani R, Nieva J and Mackman N: Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res 122: 604-609, 2008.
9. Zwicker JI: Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb Res 125 (Suppl 2): S89-S91, 2010.
10. Castellana D, Toti F and Freyssinet JM: Membrane microvesicles: Macromessengers in cancer disease and progression. Thromb Res 125 (Suppl 2): S84-S88, 2010.
11. Falanga A: Thrombophilia in cancer. Semin Thromb Hemost 31: 104-110, 2005.
12. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S and Williamson RC: Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82: 1101-1104, 1995.
13. Ueno T, Toi M, Koike M, Nakamura S and Tominaga T: Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration. Br J Cancer 83: 164-170, 2000.
14. Vrana JA, Stang MT, Grande JP and Getz MJ: Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 56: 5063-5070, 1996.
15. Gerotziafas GT, Galea V, Mbemba E, Khaterchi A, Sassi M, Baccouche H, Prengel C, van Dreden P, Hatmi M, Bernaudin JF, et al: Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res 129: 779-786, 2012.
16. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D and Dubois C: Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 206: 1913-1927, 2009.
17. Gheldof D, Mullier F, Bailly N, Devalet B, Dogné JM, Chatelain B and Chatelain C: Microparticle bearing tissue factor: A link between promyelocytic cells and hypercoagulable state. Thromb Res 133: 433-439, 2014.
18. Lacroix R and Dignat-George F: Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res 129 (Suppl 2): S27-S29, 2012.
19. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA and Weltermann A: Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97: 119-123, 2007.
20. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM and Osanto S: Microparticle-Associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost 5: 520-527, 2007.
21. Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, Kirchhofer D, Bogdanov VY, Bach RR, Rak J, et al: Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 119: 5543-5552, 2012.
22. Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S and Vasse M: Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. Blood Coagul Fibrinolysis 20: 635-641, 2009.
23. Rousseau A, Favier R and Van Dreden P: Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: New and useful markers for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol 146: 46-49, 2009.
24. Schneider P, Van Dreden P, Rousseau A, Kassim Y, Legrand E, Vannier JP and Vasse M: Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol 148: 582-592, 2010.
25. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I and Samama MM: Towards a standardization of thrombin generation assessment: The influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 3: 16, 2005.
26. Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J and Dignat-George F: Impact of pre-Analytical parameters on the measurement of circulating microparticles: Towards standardization of protocol. J Thromb Haemost 10: 437-446, 2012.
27. Bouvy C, Gheldof D, Chatelain C, Mullier F and Dogné JM: Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. J Extracell Vesicles 3: 10, 2014.
28. Key NS, Chantrathammachart P, Moody PW and Chang JY: Membrane microparticles in VTE and cancer. Thromb Res 125 (Suppl 2): S80-S83, 2010.
29. Chew HK, Wun T, Harvey D, Zhou H and White RH: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458-464, 2006.
30. Prandoni P, Falanga A and Piccioli A: Cancer and venous thromboembolism. Lancet Oncol 6: 401-410, 2005.
31. Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Möllauer L, Gnant M, Scheithauer W and Pabinger I: Microparticle-Associated tissue factor activity in patients with pancreatic cancer: Correlation with clinicopathological features. Eur J Clin Invest 43: 277-285, 2013.
32. Thaler J, Koder S, Kornek G, Pabinger I and Ay C: Microparticleassociated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res 163: 145-150, 2014.
33. Rousseau A, Van Dreden P, Larsen A, Sabbah M, Elalamy I and Gerotziafas GT: Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells. Int J Oncol (In press).
34. Castellana D, Kunzelmann C and Freyssinet JM: Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression. Hamostaseologie 29: 51-57, 2009.
35. Yu JL and Rak JW: Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2: 2065-2067, 2004.
36. Geddings JE, Hisada Y, Boulaftali Y, Getz TM, Whelihan M, Fuentes R, Dee R, Cooley BC, Key NS, Wolberg AS, et al: Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost 14: 153-166, 2016.
37. Falanga A, Panova-Noeva M and Russo L: Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 22: 49-60, 2009.
38. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC and Furie B: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15: 6830-6840, 2009.